Galderma Laboratories

Galderma is a Swiss pharmaceutical company specializing in the research, development and marketing of therapeutic, corrective and aesthetic solutions for dermatology patients and a leading player in the worldwide dermatology market. Its expertise spans a broad spectrum of skin, hair and nail diseases. In 2007, the company had global revenues of 735 million euros.

Created in 1981, Galderma is a joint venture between Nestlé and L'Oréal. Galderma employs more than 2.600 people and is headed by President & CEO Humberto C. Antunes. The company has wholly-owned affiliates in thirty-one countries and a worldwide network of exclusive sales agents. The parent company is based in Lausanne, Switzerland, with Corporate Services in Paris-La Défense, France.

To drive sustained growth, Galderma commits 14.1 percent of revenues to research and development. Three R&D centers are dedicated to the discovery and development of innovative therapeutic solutions:

• The Princeton center in New Jersey, USA (clinical development),
• The Tokyo center in Japan (clinical development).
• The Sophia Antipolis center in France which is Galderma’s largest R&D facility, employing more than 400 people.

This 19.300-sq. meter state-of-the art R&D center, dedicated exclusively to innovation in dermatology, positions Galderma as the world’s leading investor in dermatology R&D and underpins its commitment to the future of dermatology.

Galderma has also over the past years invested in high-tech production facilities:

• The Alby-sur-Chéran plant in the Haute-Savoie region of the French Alps was inaugurated in 1994. The plant currently delivers close to 23 million units per year to over fifty countries. Located at the same site, the industrial development unit takes new products from the lab to full industrial-scale production.
• The Montreal plant in Canada started production in 2000. It has a capacity of 40 million units to meet the growing demand of the North American market where Galderma makes over half of its global sales.
• Lastly, Hortolandia (state of São Paulo) in Brazil, serves the regional markets.

Galderma’s strategy for continued growth is to invest in its key brands and market them internationally (in more than sixty-five countries). Differin, the company’s first home-grown product indicated for topical treatment of acne, and other major products for treating rosacea, psoriasis and onychomycosis (fungal nail infections) are the drivers of the portfolio.

The past few years have seen profound changes in the world of dermatology, as new biotech-based treatments are introduced and more procedures are performed in dermatologists’ practices. Galderma takes part in this change and has extended its product range to include treatments for pigmentary disorders, skin cancers and medical solutions for skin senescence.

Committed to the future of dermatology, Galderma’s ambition is to be recognized as the most competent and successful innovation-based company focused exclusively on meetings the needs of dermatology patients and physicians.